AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 101 min read$AIM

AIM ImmunoTech Inc. (AIM): Entry into a Material Definitive Agreement

AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 3, 2026 and September 4, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a total of two exchange agreements (the “Exchange Agreements”) and, for each, a corresponding partitioned promissory note (together,

Original reporting
SEC EDGAR 8-K
Published Sep 10, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$AIM
Neutral
medium confidence
Mentioned
$AIM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AIMNeutralLow
01

Why it matters

The note conversion adds ~1.9M shares, modestly increasing supply and slightly diluting existing holders.

02

Market read

Primary disclosure of a small‑scale equity conversion; low trading relevance.

03

What to watch

Potential future financing needs if cash flow remains tight.

Relevance 6/10Novelty 5/10Timing: filed Sep 10 2026

Background

SEC Form 8‑K reporting entry into material definitive agreements and unregistered equity sales.

Company-level read

Ticker impact

$AIMNeutralMedium confidence
Context

AIM ImmunoTech converted $450,000 of a promissory note into 1.92M shares, diluting equity and increasing float.

Expected impact

minor short‑term dip, limited long‑term effect

Evidence & confidence

Small capital raise via note conversion; no new cash infusion, but dilution of existing shareholders.

Market effects

Sector

Limited impact on biotech sector; similar note conversions are common.

Regional

US market only; no broader regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The dilution could be viewed as a sign of cash constraints, suggesting caution.

Key entities

  • company
    AIM ImmunoTech Inc.

    Biotech firm listed on Nasdaq under ticker AIM.

  • lender
    Streeterville Capital, LLC

    Counterparty to the exchange agreements.

Read at source← All news

Related articles

AUG 10
$AIMLow

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3…

AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer Completed Enrollment and Ampligen Do

SEC EDGAR 8-K2 min
JUL 23
$AIMMedAI 8/10

AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead

AIM ImmunoTech said its Phase 2 pancreatic cancer trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) after FOLFIRINOX reached final patient enrollment ahead of schedule. The company expects to complete dosing and assess the primary Clinical Benefit Rate endpoint in December 2026, while continuing Phase 3 planning and expanding regulatory and IP efforts.

stocktwits.com4 min
JUL 9
$AIMMed

WA gold project Warrawoona fined $118,000 over threatened bat

Australia’s DCCEEW fined AIM Mining Corporation $118,000 for EPBC breaches at its Warrawoona Gold Project in WA’s Pilbara, tied to failure to protect the threatened Pilbara leaf-nosed bat. The regulator cited groundwater extraction over limits, missing species management steps, and reporting failures. AIM said it paid the fine. Calidus previously operated the project.

abc.net.au4 min